ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Selection of resistance-conferring mutations in HIV-1 by the nucleoside reverse transcriptase inhibitors (+/-)dOTC and (+/-)dOTFC.
 PMID: 11227993       2000       Antiviral chemistry & chemotherapy
Abstract: A substitution of methionine to valine was identified at position 184 (M184V) in variants selected with (+/-)dOTC.
Abstract: Studies with mutated recombinant HXB2D-M184V and -K65R confirmed that these mutations are important for phenotypic resistance in MT-2 cells.


  Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase.
 PMID: 10413520       1999       Biochemistry
Abstract: A dramatic 146- and 117-fold decrease in incorporation efficiency was observed for 3TC-MP incorporation by M184V RT for DNA- and RNA-dependent DNA polymerization, respectively, as compared with wild-type HIV-1 RT.
Abstract: A single amino acid substitution from methionine-184 to valine (M184V) of HIV-1 reverse transcriptase (RT) evokes the 1000-fold 3TC (Lamivudine) resistance by the HIV-1 virus observed in the clinic.
Abstract: The M184V mutant HIV


  Long-term evaluation of triple nucleoside therapy administered from primary HIV-1 infection.
 PMID: 10416525       1999       AIDS (London, England)
Abstract: M184V and/or T215Y mutations were demonstrated in two of these last five patients.


  Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine, and protease inhibitors.
 PMID: 10421243       1999       Journal of acquired immune deficiency syndromes (1999)
Abstract: Among ZDV-resistant study subjects at week 24 (n = 17), those with mutant RT M184V codon had a more favorable HIV-1 RNA slope than those with wild-type RT 184M codon (p = .0551).
Abstract: Emergence of the M184V RT mutation at week 48 was detected in 3 of 16 (18.7%) initially drug-naive subjects as opposed to 21 of 40 (52.5%) ZDV-pretreated patients.
Abstract: Multivariate logistic analysis detected HIV-1 RNA load at week 24 as the best predictor of subsequent selection of the M184V mutant (p = .0121).


  Presence of mutation conferring resistance to lamivudine in plasma and cerebrospinal fluid of HIV-1-infected patients.
 PMID: 10428105       1999       Journal of acquired immune deficiency syndromes (1999)
Abstract: In 4, the lamivudine (3TC)-resistance mutation M184V was found in both CSF and plasma.
Abstract: In both, M184V was found in plasma but not CSF.


  A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine.
 PMID: 10428942       1999       Antimicrobial agents and chemotherapy
Abstract: A similar increase in susceptibility to AZT and to PMPA was also conferred by the M184V mutation in RT.


  Resistance profiles of (+)2'-deoxy-3'-oxa-4'-thiocytidine and (-)2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine.
 PMID: 10432679       1999       Nucleosides & nucleotides
Abstract: Cloning and sequencing of the RT genes of the selected viruses identified two mutations, M184I for (+) dOTC and M184V for (-) dOTFC.


  Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potential.
 PMID: 10449287       1999       AIDS (London, England)
Abstract: Met184Val and Met184Ile, result in an increase in polymerase fidelity of the enzyme as measured in biochemical assays; however, the effect of such changes on the fidelity during viral replication is largely unknown.
Abstract: CONCLUSION: This study demonstrates that the Met184Val and Met184Ile mutations in the HIV-1 reverse transcriptase enzyme do not significantly affect the evolutionary potential of the corresponding viruses.
Abstract: DESIGN AND METHOD: In vitro selection experiments with either wild-type or lamivudine-resistant viruses (Met184Val and Met184Ile) were performed using a protease inhibitor as the selective drug.


  Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity.
 PMID: 10458616       1999       Journal of acquired immune deficiency syndromes (1999)
Abstract: An HIV strain encoding the M184V mutation was susceptible to the combination of MA and abacavir.


  Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.
 PMID: 10482597       1999       Journal of virology
Abstract: In replication kinetics assays, mutant Leu74Val replicated slower than the mutant Met184Val.
Abstract: The replication kinetics and RT processivity of the mutant with the Leu74Val mutation were compared to those of a lamivudine-selected mutant Met184Val.
Abstract: These observations provide biochemical evidence of decreased processivity to support the decrease in replication fitness observed with the Leu74Val or Met184Val mutations.



Browser Board

 Co-occurred Entities




   Filtrator